No significant changes were witnessed in the levels of CD45+CD8+ T cells and CD45+CD4+ T cells (Figs. 4A and 4C), but those of CD45+CD8+IFN-γ+ T cells and CD45+CD4+IFN-γ+ T cells increased obviously (Figs. 4B and 4D), indicating activation of these immune cells in the tumor microenvironment (TME) upon the induction from the combination of venetoclax and fruquintinib. The gene discussed is IFNG; the disease is neoplasm.